ArticleLaryngoscope investigative otolaryngology2026
Adjuvant HPV Vaccination and Survival in Oropharyngeal Squamous Cell Carcinoma: An Exploratory Analysis of a Real-World Database.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: Childhood HPV vaccination reduces oropharyngeal cancer (OPC) incidence, but evidence regarding vaccination after HPV exposure or OPC diagnosis remains limited. While benefits are documented in cervical dysplasia, anogenital cancers, and laryngeal papillomatosis, the impact on OPC outcomes is unknown. Methods: Using the prospective TrinetX database, OPC patients were stratified by HPV vaccination status. Vaccinated patients were divided into three cohorts: vaccinated before OPC diagnosis, within 1 year after diagnosis, and at any timepoint. Cohorts were propensity-matched with unvaccinated controls by age, race, ethnicity, sex, and cancer stage. Survival outcomes were assessed at 2, 5, and > 5 years post-diagnosis using absolute risk reduction and Kaplan-Meier analyses. Results: Propensity matching yielded 162 patients vaccinated at any time, 24 vaccinated within 1 year post-diagnosis, and 79 vaccinated pre-diagnosis, with equal matched controls showing no demographic differences. Women predominated among those vaccinated before OPC diagnosis (73%), while men comprised 80% of those vaccinated after diagnosis. HPV vaccination was associated with improved overall survival at 2 years (97% vs. 91%, Conclusion: HPV vaccination after HPV exposure was associated with improved survival in OPC patients. However, imperfect HPV ascertainment, small vaccinated cohorts, and potential selection bias, including a healthy vaccinee effect, preclude causal inference, and this association should not be interpreted as evidence of a therapeutic effect. Prospective and randomized clinical trials are needed to determine whether adjuvant HPV vaccination confers a true survival benefit in OPC. Given the low morbidity of therapy and high potential survival impact, a clinical trial is warranted. Level of Evidence: 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.